Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 2016 (2016), Article ID 5128720, 8 pages
Research Article

Autoantibody Response to ZRF1 and KRR1 SEREX Antigens in Patients with Breast Tumors of Different Histological Types and Grades

1Department of Cell Signaling, Institute of Molecular Biology and Genetics NASU, Kyiv, Ukraine
2Institute of Fundamental Medicine and Biology, Kazan Federal University, Kazan, Russia
3Breast Cancer Department, National Cancer Institute, Kyiv, Ukraine
4Department of Oncological Pathology, Dnipropetrovsk Regional Center of Pathology, Dnipropetrovsk, Ukraine

Received 20 June 2016; Revised 30 August 2016; Accepted 29 September 2016

Academic Editor: Szilárd Nemes

Copyright © 2016 Lada Dyachenko et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Purpose. To investigate a frequency of antibody response to SEREX-identified medullary breast carcinoma autoantigens ZRF1 and KRR1 in sera of breast cancer patients taking into account clinical and molecular characteristics of tumors for opening of new perspectives in creation of minimally invasive immunological tests for cancer diagnostics. Methods. Enzyme-linked immunosorbent assay and bioinformatics analysis. Results. Increased frequency of antibody response was found in sera of breast cancer patients to ZRF and KRR1 antigens. The antibody response to these antigens was higher in sera of patients with invasive ductal carcinoma than in sera of patients with other histological types of breast tumors. Moreover, more frequent antibody response to ZRF antigen was found in sera of patients with less aggressive tumors. The sequence analysis of ZRF1 antigen SEREX clones obtained from cDNA libraries of different tumors demonstrates that they encode different protein isoforms. Conclusion. Tumor-associated antigens KRR1 and ZRF1 and their cognate autoantibodies could be considered as potential molecular markers of breast cancer which need to be further investigated.